Trump’s FDA Wants to Talk About Abortion Pills After the Election. Let’s Talk About Them Now.

We can’t take our eyes off the FDA, including and especially when we head to the ballot box.

Robert F. Kennedy Jr. and Donalt Trump sit next to each other as they speak to reporters in the White House.
Secretary of Health and Human Services Robert F. Kennedy Jr. speaks, while President Donald Trump listens, in the East Room of the White House on July 30, 2025. (Jim Watson / AFP via Getty Images)

This article was originally published by The Contrarian, as “Hiding Until After the Mid-Terms Won’t Work.”

No surprise, the Food and Drug Administration now plans to hold off on releasing its so-called safety review of mifepristone—the drug most often used in medication abortions—until March 2027, when the midterms will be safely in the rearview mirror.

Feminists have been following the study ever since HHS Secretary Robert F. Kennedy Jr. commissioned it in 2025. All along, the assignment has smacked of a pressure campaign from the antiabortion base, furious that abortion rates haven’t dropped since the Dobbs v Jackson Women’s Health Organization decision in 2022.

… If the FDA reports anything contrary to its prior findings, it would be serving up a justification to curb access, which would have a nationwide impact—even in states where abortion is still legal.

According to a court-ordered update filed earlier this month by the Justice Department, the FDA study intends to compare the safety and side effects of mifepristone versus surgical abortions in 100,000 women. This is the first public accounting of the plan, which has largely been kept under wraps.

Why has the FDA been so hush-hush? It’s certainly no secret the drug has a long-documented and well-established safety and efficacy record since its 2000 approval. It is pretty clear the study is more about providing a gesture to the angry Trump base and engaging in a grand stall tactic.

At the end of the day, if the FDA reports anything contrary to its prior findings, it would be serving up a justification to curb access, which would have a nationwide impact—even in states where abortion is still legal. And though that may be a fever dream for conservatives, Donald Trump and his acolytes know full well it would be wildly unpopular with an already agitated electorate.

Translation: They’re laying low until after the midterms.

Dr. Heidi Overton, a woman with blond hair wearing a burgundy and black suit, pulls out her chair to sit at a microphone in a courtroom.
President Donald Trump nominated Dr. Heidi Overton in August 2026 to become the permanent FDA commissioner. Kyle Diamantas currently serves as acting commissioner. The Senate won’t vote on her confirmation until after the midterms. (Tom Williams / CQ-Roll Call, Inc via Getty Images)

There are a few other sticky aspects to note about the timing. First and foremost, the FDA is currently without leadership. Trump’s pick to be the next commissioner, Dr. Heidi Overton, staunchly opposes abortion rights, including medication abortion. She’s made no bones about what her priority will be if given full reign. The Senate won’t vote on her confirmation until after the midterms.

And then there is the administration’s role in defending a Louisiana lawsuit challenging the telehealth provision of mifepristone. The case has been a roller coaster: After a federal appeals court granted the state’s request to reinstate a nationwide requirement that mifepristone be dispensed only in person, the Supreme Court blocked that decision while the litigation plays out. Meanwhile, the Justice Department has been tepid in its defense, attempting to call as little attention as possible to the massive ramifications.

In the court papers filed earlier this week in response to the court’s demand for an update on the safety review—thank you again to the judiciary for demanding daylight—the Justice Department indicated it may indeed re-evaluate telehealth rules based on the FDA’s new data.

Don’t let the administration’s lack of bravado here be a distraction from its real endgame. None of us can afford to take our eyes off the FDA, including and especially when we head to the ballot box. The administration’s goal of enacting what would amount to a nationwide abortion ban is a stealth campaign that will catch up to us after we’ve voted. That’s a blow to democracy we can’t afford.

*

A note from Ms. editors: We want to hear from you for The Majority, a new campaign collecting stories about how reproductive freedom has enabled readers to build the lives they want and need.

Poll after poll shows a majority of Americans support reproductive healthcare access. Yet public debate overlooks the lives shaped by abortion access, contraception, IVF, miscarriage care, maternal healthcare or comprehensive sex education—countless women who chose to pursue an education, have children, not have children, protect their health and chart their own future. What’s your reproductive freedom story? Add your voice. Together, these stories will help show not only why reproductive freedom remains a majority value, but also what it makes possible. 

About

Jennifer Weiss-Wolf is the executive director of Ms. partnerships and strategy. A lawyer, fierce advocate and frequent writer on issues of gender, feminism and politics in America, Weiss-Wolf has been dubbed the “architect of the U.S. campaign to squash the tampon tax” by Newsweek. She is the author of Periods Gone Public: Taking a Stand for Menstrual Equity, which was lauded by Gloria Steinem as “the beginning of liberation for us all,” A Citizen’s Guide to Menopause Advocacy, together with Dr. Mary Claire Haver (featuring a foreword by Maria Shriver); and When in Menopause: A User’s Manual and Citizen’s Guide. She is also the executive director of the Birnbaum Women’s Leadership Center at NYU Law.